Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses

Hiroyuki Kishimoto,1,2,3 Yasuo Urata,5 Noriaki Tanaka,3,4 Toshiyoshi Fujiwara,3,4 and Robert M. Hoffman1,2

1AntiCancer, Inc.; 2Department of Surgery, University of California, San Diego, California; 3Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 4Center for Gene and Cell Therapy, Okayama University Hospital, Okayama, Japan; and 5Oncolys BioPharma, Inc., Tokyo, Japan

Abstract
We previously constructed telomerase-dependent, replication-selective adenoviruses OBP-301 (Telomelysin) and OBP-401 [Telomelysin-green fluorescent protein (GFP); TelomeScan], the replication of which is regulated by the human telomerase reverse transcriptase promoter. By intratumoral injection, these viruses could replicate within the primary tumor and subsequent lymph node metastasis. The aim of the present study was to evaluate the possibility of systemic administration of these telomerase-dependent adenoviruses. We assessed the antitumor efficacy of OBP-301 and the ability of OBP-401 to deliver GFP in hepatocellular carcinoma (HCC) and metastatic colon cancer nude mouse models. We showed that i.v. administration of OBP-301 significantly inhibited colon cancer liver metastases and orthotopically implanted HCC. Further, we showed that OBP-401 could visualize liver metastases by tumor-specific expression of the GFP gene after portal venous or i.v. administration. Thus, systemic administration of these adenoviral vectors should have clinical potential to treat and detect liver metastasis and HCC. [Mol Cancer Ther 2009;8(11):3001–8]

Introduction
Primary and metastatic liver tumors are a common cause of death throughout the world. Hepatocellular carcinoma (HCC), the most common primary liver tumor, is the fifth most common malignancy and the third most frequent cause of cancer death worldwide (1, 2). HCC often metastasizes widely, and distant metastatic sites include lung, bone, adrenals, and brain. The 5-year survival rates of these patients are usually in the range of 16% to 25% (3). Colorectal cancer is also one of the most common tumors worldwide. The liver is the most preferential site for metastasis of colorectal cancer and over half of these patients die from their metastatic liver diseases (4). Therefore, management of the liver metastases is a key factor for colorectal cancer prognosis.

Liver resection is the only potentially curative treatment option available for patients with primary and metastatic liver tumors (5, 6). However, because only a minority of patients with colorectal liver metastases or HCC are candidates for surgery (7–10), new therapeutic agents and innovative approaches for tumor detection are desired.

We previously constructed two conditionally replicating type 5 adenoviruses OBP-301 (Telomelysin) and OBP-401 [Telomelysin-green fluorescent protein (GFP); TelomeScan]. The replication of these viruses is regulated by the human telomerase reverse transcriptase (hTERT) promoter (11–15). hTERT is the catalytic subunit of telomerase, which is highly active in cancer cells but quiescent in most normal somatic cells (16). Therefore, these adenoviruses have tumor-specific replication regulated by the hTERT transcriptional activity. OBP-301 has shown a strong anticancer efficacy in a variety of tumors in vitro and in vivo (11, 12, 17–19). We also reported that OBP-401 can replicate in and label cancer cells with GFP in vitro and in vivo and thereby enables imaging of tumor cells by GFP fluorescence in vivo (15). Tumor specificity is conferred by selective replication of OBP-401 in the cancer cells. Replication of the virus, and therefore production of GFP, depends on the tumor-specific expression of telomerase. In those studies, however, the virus was administered locally such as by intratumoral injection or administration into a body cavity (thoracic or abdominal cavity). The efficacy of these viruses, when administered systemically, has not been evaluated.

In the present study, we examined the feasibility of systemic administration of OBP-301 and OBP-401 to colorectal liver metastases and to orthotopic HCC tumor in nude mice models, focusing on the antitumor efficacy of OBP-301 and the ability of OBP-401 to selectively induce GFP gene expression in cancer cells.

Materials and Methods
Recombinant Adenovirus
We previously constructed OBP-301, in which the hTERT promoter element drives the expression of the E1A and E1B genes linked with an internal ribosome entry site (11–14).
OBP-401, was derived from OBP-301 and also contains the GFP gene under the control of the cytomegalovirus promoter, was also constructed previously (15, 20). These viruses were purified by ultracentrifugation in cesium chloride step gradients. Their titers were determined by a plaque-forming assay using 293 cells. The viruses were stored at −80°C.

Cell Culture

The human colorectal cancer cell line HCT-116 and the human HCC cell lines Hep3B and HepG2 were obtained from the American Type Culture Collection. The cells were cultured in RPMI 1640 (Irvine Scientific) supplemented with 10% fetal bovine serum.

**GFP Gene Transduction of Cancer Cells**

For GFP gene transduction of cancer cells, 20% confluent HCT-116 or Hep3B cells were incubated with a 1:1 precipitated mixture of retroviral supernatants of the PT67 GFP-expressing packaging cells and RPMI 1640 containing 10% fetal bovine serum for 72 h. Fresh medium was replenished at this time. Tumor cells were harvested by trypsin/EDTA 72 h post-transduction and subcultured at a ratio of 1:15 into selective medium containing 200 μg/mL G418. The level of G418 was increased up to 800 μg/mL in a stepwise manner. GFP-expressing cancer cells were isolated with cloning cylinders (Bel-Art Products) using trypsin/EDTA and amplified by conventional culture methods in the absence of selective agent.

**Animal Experiments**

Athymic nude mice were kept in a barrier facility under HEPA filtration and fed with autoclaved laboratory rodent diet (Teklad LM-485; Western Research Products). All animal studies were conducted in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals under assurance no. A3873-1. All animal procedures were done under anesthesia using s.c. administration of a ketamine mixture (10 μL ketamine HCl, 7.6 μL xylazine, 2.4 μL acepromazine maleate, and 10 μL PBS).

**Experimental Liver Metastasis Model of Human Colon Cancer**

To generate a liver metastasis model, unlabeled HCT-116 or HCT-116-GFP human colon cancer cells were injected...
at a density of $2 \times 10^6$ in 50 $\mu$L Matrigel (BD Biosciences) into the spleen of nude mice, and the liver was excised 6 wk later. OBP-301 or PBS were i.v. injected 5 d after tumor cell inoculation. Excised livers were photographed under bright light (top). Fluorescence imaging showed GFP expression signals on the HCT-116-GFP liver metastasis (bottom). B, macroscopic appearance of lungs. Lung metastatic foci were detected with GFP fluorescence. Left, control; right, OBP-301 treatment significantly suppressed lung metastasis. C, H&E staining of lung metastasis in control mouse (green arrow). Left, magnification, $\times 40$; right, protrusion of tumor (green arrow) into the adjacent alveoli through the Kohn’s pore (yellow arrow). Magnification, $\times 400$. D, quantitative analysis of the total GFP intensity in the liver of control and OBP-301–treated mice ($P < 0.05$). E, quantitative analysis of the number of lung metastases of control and OBP-301–treated mice ($P < 0.05$).

Orthotopic Liver Tumor Model of HCC

An orthotopic liver tumor model with human HCC was made with unlabeled Hep3B or Hep3B-GFP human HCC cells. Unlabeled Hep3B or Hep3B-GFP cells ($5.0 \times 10^6$ in $10 \mu$L Matrigel) were subserosally injected into the left lobe of the liver through a 28-gauge needle at laparotomy. Unlabeled HepG2 cells, cells ($3 \times 10^6$ in $50 \mu$L Matrigel) were injected into the spleen of nude mice through a 28-gauge needle at laparotomy.

Antitumor Efficacy Studies

To assess the antitumor efficacy of i.v. administration of OBP-301 against liver metastases of the colorectal cancer, OBP-301 was injected once systemically into the tail vein at a dose of $5 \times 10^8$ plaque forming units (PFU)/100 $\mu$L 5 days after HCT-116-GFP cells were injected into the spleen. Control mice were injected with 100 $\mu$L PBS in an identical manner ($n = 9$ mice per group). Six weeks after tumor cell inoculation (5 weeks after treatment), fluorescence imaging was done using an Olympus OV100 Imaging System. GFP fluorescent intensity of the liver metastases and the number of lung metastases were determined. To obtain GFP intensity, exposure conditions were maintained constant at 30 ms to keep the data comparable. GFP intensity was quantified and presented in the units of SUM green intensity using Cell software (Olympus-Biosystems). The experimental data are presented as mean ± SD. Comparison of the GFP intensity and the number of lung metastases between the treatment and control groups were analyzed using a two-tailed Student’s $t$ test.

The antitumor efficacy of i.v. administration of OBP-301 was also assessed in an orthotopic liver tumor model of HCC. OBP-301 was i.v. injected biweekly ($5 \times 10^8$ PFU/2 weeks for 6 weeks) starting from 2 weeks after Hep3B-GFP cells were injected into the liver. Control mice were injected with 100 $\mu$L PBS in an identical manner ($n = 9$ mice per group). All animals were examined 8 weeks after cancer cell inoculation (2 weeks after last treatment). Development of tumor growth and response to OBP-301 treatment were evaluated by the fluorescent area of the liver tumor calculated by Cell software using GFP images obtained with the Olympus OV100. The experimental data are presented as
mean ± SD. Comparison of the tumor area between the treatment and control groups was analyzed using a two-tailed Student's t test.

**Viral GFP Labeling of Tumors**

To assess the tumor detection ability of OBP-401 for metastatic liver tumors, a liver metastasis model of unlabeled HCT-116 cells was used. OBP-401 was injected i.v. or intrasplenically at a dose of $1 \times 10^8$ PFU/mouse. Animals were examined at laparotomy by fluorescence imaging with the OV100 5 days after OBP-401 was administered. Some mice had a second-look observation 1 week after the first open examination.

To assess the tumor detection ability of OBP-401 in the orthotopic liver tumor model, unlabeled Hep3B cells were

---

**Figure 3.** Portal venous delivery of OBP-401 selectively labeled multiple colon cancer liver metastases. **A**, gross appearance of the abdominal cavity (mouse no. 1). Five days after splenic injection of OBP-401, HCT-116 liver metastases were visualized by GFP fluorescence. **B**, higher magnification of the liver surface indicated by the white circle in **A**, **C**, liver metastases were visualized by GFP fluorescence in mouse no. 2.

**Figure 4.** Selective GFP labeling of multiple liver metastases of human colon cancer by i.v. injection of OBP-401. **A** to **C**, 5 d after i.v. injection with OBP-401, HCT-116 liver metastases were visualized by GFP fluorescence (mouse nos. 1-3, left). Higher magnification of the liver metastasis indicated by a white circle (right). **D**, gross appearance of the abdominal cavity (mouse no. 4). **E**, macroscopic appearance of excised liver in mouse no. 4. The margin of the liver metastasis was visualized by GFP fluorescence. **F**, macroscopic appearance of spleen. Tumor development in the spleen was also visualized by GFP fluorescence 5 d after OBP-401 treatment (red arrow).
used. OBP-401 was injected systemically into the tail vein at a dose of $1 \times 10^8$ PFU/mouse 2 weeks after tumor cell inoculation. Animals were examined at laparotomy by fluorescence imaging with the OV100 5 days after OBP-401 was administered. Some mice had a second-look observation 4 weeks after i.v. injection of OBP-401.

**Fluorescence Optical Imaging and Processing**

The Olympus OV100 Imaging System containing an MT-20 light source was used. High-resolution images are captured directly on a PC (Fujitsu Siemens), and images are analyzed with the use of Cell software (Olympus-Biosystems).

**Results and Discussion**

**Liver Metastasis Model of Human Colon Cancer**

Intrasplenic inoculation of nude mice with unlabeled HCT-116 or HCT-116-GFP human colon cancer cells led to multiple experimental metastases in the liver within 14 days. With HCT-116-GFP, spleen tumors and lung metastasis could also be observed by fluorescence imaging at 6 weeks after cancer cell implantation.

**Orthotopic Liver Tumor Model of HCC**

When unlabeled Hep3B or Hep3B-GFP human HCC cells were subserosally injected into the liver of nude mice (Fig. 1A), a small tumor mass (~2 mm) was often observed on the liver surface by 2 weeks after cancer cell inoculation. Hep3B liver tumors usually grew only in the injected lobe and rarely spread to other lobes (Fig. 1B). These tumors showed abundant tumor blood vessels, indicating a rich blood supply for the tumor, which reflects HCC in human patients (Fig. 1C).

Unlabeled HepG2 cells were also inoculated in the spleen of nude mice with the same technique used in the experimental colorectal liver metastasis model. Two weeks after tumor cell inoculation, multiple HepG2 tumors were observed on the liver surface.

**Inhibition of Experimental Colon Cancer Metastasis by OBP-301**

OBP-301 was i.v. injected at a dose of $5 \times 10^8$ PFU/mouse 5 days after HCT-116-GFP inoculation in the spleen. At 6 weeks after HCT-116-GFP colon cancer cell inoculation, 100\% of the control animals developed liver tumors, and tumors in the spleen developed in 40\% of control animals. Treatment with OBP-301 caused a significant inhibition in liver metastasis growth ($P < 0.05$; Fig. 2A and D). Additionally, OBP-301–treated animals showed a reduced number of lung metastases colonies compared with controls ($P < 0.05$; Fig. 2B and E). These results show that systemic dosing of OBP-301 has significant antitumor activity against experimental colon cancer liver metastasis. In contrast to the experimental liver metastasis, OBP-301 did not have an apparent effect on the spleen tumors. The lack of effect of OBP-301 on the spleen tumors may be because of their very small size, which made differences difficult to discern.

**Inhibition of Orthotopic HCC by OBP-301**

To evaluate the antitumor efficacy of OBP-301 on HCC tumors, the orthotopic liver tumor model of Hep3B-GFP was used.

---

**Figure 5.** Early metastatic liver tumors not otherwise clearly visible could be visualized after i.v. injection of OBP-401. **A,** cross-sections of liver. GFP expression was mainly located at the periphery of the liver metastases. Tiny metastatic foci not otherwise clearly visible were visualized by GFP fluorescence after i.v. injection of OBP-401 (yellow arrow). **B,** 5 d after i.v. injection of OBP-401, HCT-116 liver metastases were visualized by GFP fluorescence (red circle). There were areas in the liver, which had GFP expression but seemed to be tumor-free in bright light (blue circle). Seven days later, metastases could be visualized by bright light as well as GFP fluorescence (yellow arrows), showing the power of OBP-401 to label very early, otherwise invisible metastases with GFP.
The colorectal liver metastasis model was made by delivering cells into the portal vein as described above, whereas the orthotopic HCC model was made by injecting cells directly into the hepatic parenchyma, where at the early stage of tumor development most cells were thought to locate outside of the blood vessels. Thus, i.v. injected OBP-301 could target cancer cells more effectively in the colorectal liver metastasis model than in the HCC model. In the HCC model, therefore, we increased the number of injections of OBP-301, which was administered biweekly (5 × 10^8 PFU/2 weeks i.v. for 6 weeks) starting 2 weeks after tumor cell inoculation. Treatment of OBP-301 caused a significant inhibition in liver tumor growth (P < 0.01; Fig. 1D and E). These results show that systemic dosing of OBP-301 has significant antitumor activity against Hep3B-GFP human HCC tumors.

**Selective Visualization of Colorectal Liver Metastases by OBP-401 Delivery of the GFP Gene**

To assess the tumor detection ability of OBP-401 for colorectal liver metastases, OBP-401 was administrated to mice by portal venous delivery or systemic delivery using the tail vein. Animals with HCT-116 experimental liver metastases were intrasplenically injected with OBP-401 (1 × 10^8 PFU/mouse) 12 days after tumor cell inoculation. The spleen was used to access the portal venous circulation. Five days after injection of OBP-401, the liver metastases could be visualized by GFP fluorescence. Representative mice are shown in Fig. 3. Cross-sections of the liver also showed tiny metastatic foci visualized by GFP fluorescence (Fig. 5A). Moreover, a second-look observation done 1 week after the first laparotomy showed that early metastatic liver tumors, not clearly visible under bright light, had been visualized with GFP fluorescence after i.v. injection of OBP-401 at as early as day 5, indicating the possibility of early detection.

![Image](https://example.com/image.png)
detection of metastatic disease (Fig. 5B). When injected with more than $2 \times 10^8$ PFU of OBP-401, mice often showed GFP fluorescence in normal tissues such as liver, lung, spleen, and thoracic duct (data not shown). Theses results suggest that colorectal liver metastases can be visualized by GFP fluorescence both by portal venous and i.v. administration of OBP-401.

**Selective Visualization of Orthotopic HCC by OBP-401**

Five days after injection of OBP-401 ($1 \times 10^8$ PFU/mouse) into the tail vein, HCC liver tumors were visualized by GFP fluorescence (Fig. 6A). Cross-sections of the liver at 4 weeks after i.v. injection of OBP-401 showed that GFP expression was in the cancer cells and not in normal cells (Fig. 6B and C). Small liver tumor nodules were also visualized by GFP fluorescence after i.v. OBP-401 administration (Fig. 6D). Thus, we showed that HCC liver tumors could be selectively visualized by GFP fluorescence after i.v. injection of OBP-401.

Many studies have shown that the majority of malignant human tumors tested express hTERT. OBP-301 and OBP-401 specifically replicate in tumors due to hTERT expression in tumors (11, 12, 17–19). In previous studies, OBP-301 and OBP-401 were administered locally, such as by intratumoral or intraperitoneal administration. The present report shows the systemic efficacy of OBP-301 and OBP-401 to selectively replicate in and kill primary and metastatic liver tumors after i.v. administration. Closely related virus constructs will be compared with OBP-301 and OBP-401 in the future.

Our laboratory pioneered the use of fluorescent proteins to visualize cancer cells in vivo. Cancer cells genetically labeled by fluorescent proteins have increased the possibility and sensitivity to observe progression of cancer cells in live animals (21). To evaluate antitumor efficacy of i.v. administration of OBP-301 against primary and metastatic liver tumors, we used GFP-expressing human cancer cell lines. We showed that i.v. administration of OBP-301 resulted in a significant reduction in experimental liver and pulmonary metastases in a colorectal liver metastases model and effectively inhibited tumor formation and growth in an orthotopic HCC model. OBP-401 has less but still significant cytotoxic effects compared with OBP-301 (22). In fact, a significant inhibition of tumor growth by intratumoral injection of OBP-401 was confirmed in vivo in our previous study (20). However, OBP-401 at the tumor-selective labeling dose used in this i.v. injection study could not inhibit tumor growth effectively.

The imaging strategy using OBP-401 has a potential of being available in humans as a navigation system in the surgical treatment of malignancy. During surgery, tumors that would be difficult to detect by direct visual detection could be positively identified with GFP fluorescence using a handheld excitation light and appropriate filter goggs as we have shown previously in mice (23–25). Employment of a fluorescence surgical microscope would enable visualization of the GFP-expressing microscopic leading edge of the tumor and allow accurate resection with sufficient margins.

As for toxicity of OBP-301 and OBP-401, only when injected with $5 \times 10^8$ PFU OBP-301 for the first time, a few mice showed lethargy but fully recovered within 1 h. None of the mice treated with OBP-301 or OBP-401 at the doses used in this study showed significant adverse effects during the observation period or histopathologic changes in the liver at the time of sacrifice. In the near future, the safety of OBP-301 will be confirmed in a phase I clinical trial, which is currently under way (26).

Our studies suggest the clinical potential of OBP-301 and OBP-401.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**References**


Molecular Cancer Therapeutics

Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses

Hiroyuki Kishimoto, Yasuo Urata, Noriaki Tanaka, et al.


Updated version

Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-09-0556

Cited articles

This article cites 26 articles, 6 of which you can access for free at:
http://mct.aacrjournals.org/content/8/11/3001.full.html#ref-list-1

Citing articles

This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/8/11/3001.full.html#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.